ADAR1: A New Target for Immuno-oncology Therapy
Copyright policy )ADAR1: A New Target for Immuno-oncology Therapy
Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.
- Stanford University United States
Gene Editing, Interferon-Induced Helicase, IFIH1, Adenosine Deaminase, Cell Survival, RNA-Binding Proteins, Genetic Therapy, Gene Expression Regulation, Enzymologic, Immunity, Innate, Gene Expression Regulation, Neoplastic, Neoplasms, Animals, Humans, Immunotherapy, RNA Editing, CRISPR-Cas Systems, RNA, Double-Stranded
Gene Editing, Interferon-Induced Helicase, IFIH1, Adenosine Deaminase, Cell Survival, RNA-Binding Proteins, Genetic Therapy, Gene Expression Regulation, Enzymologic, Immunity, Innate, Gene Expression Regulation, Neoplastic, Neoplasms, Animals, Humans, Immunotherapy, RNA Editing, CRISPR-Cas Systems, RNA, Double-Stranded
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).57 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!